Real Paley-Wiener type theorems for the Dunkl transform on {\mathcal{S}}'(\mathbb{R}^{d})

We prove real Paley-Wiener type theorems for the Dunkl transform ℱ _D on the space of tempered distributions. Let T∈S′(ℝ ^d ) and Δ _κ the Dunkl Laplacian operator. First, we establish that the support of ℱ _D (T) is included in the Euclidean ball , M>0, if and only if for all R>M we have lim  _n→+∞ R ⁻²ⁿ Δ _κ ⁿ T=0 in S′(ℝ ^d ). Second, we prove that the support of ℱ _D (T) is included in ℝ ^d ∖B(0,M), M>0, if and only if for all R<M, we have lim  _n→+∞ R ²ⁿ  ℱ _D ⁻¹(‖y‖⁻²ⁿ ℱ _D (T))=0 in S′(ℝ ^d ). Finally, we study real Paley-Wiener theorems associated with -slowly increasing function.      

Simulation on semiconductor optical amplifier intensity noise reduction for future spectrum-sliced optical networks

Spectrum-slicing techniques employing incoherent light are an economic, practical and therefore attractive solution for future all-optical networks, especially for wavelength-division multiplexing (WDM) transmission systems in local area networks (LAN). However, spectrum-sliced methods exhibit a large excess intensity noise factor that limits the performance of the system. In this paper, we investigate noise suppression of spectrum-sliced incoherent light using a saturated semiconductor optical amplifier (SOA). The system incorporating the noise reducing SOA is modeled and simulated using OptSim software, and the results are compared to practical schemes from the literature. Performance comparisons are made with two different broadband sources test-beds. The characteristics of the SOA gain saturation are also presented. In both cases, it is found that a high degree of intensity noise is suppressed by the use of the non-linear gain saturation characteristics of the SOA so as to achieve better system performance. The position of a modulator in the system is also investigated in order to greatly reduce the excess intensity noise.     

Infection Dynamics of ATG8 in Leishmania: Balancing Autophagy for Therapeutics

In many regions of the world, Leishmaniasis is a cause of substantial mortality and ailment. Due to impediment in available treatment, development of novel and effective treatments is indispensable. Significance of autophagy has been accentuated in infectious disease as well as in Leishmaniasis, and it is having capability to be manifested as a therapeutic target. By evincing autophagy as a novel therapeutic regime, this study emphasized on the critical role of ATG4.1-ATG8 and ATG5-ATG12 complexes in Leishmania species. The objective here was to identify ATG8 as a potential therapeutic target in Leishmania. R71T, P56E, R18P are the significant mutations which shows detrimental effect on ATG8 while Arg276, Arg73, Cys75 of ATG4.1 and Val88, Pro89, Glu116, Asn117, and Gly120 are interacting residues of ATG8. Along with this, we also bring into spotlight an enticing role of Thiabendazole derivatives that interferes with the survival mechanisms by targeting ATG8. Further, the study claims that thiabendazole can be a potential drug candidate to target autophagy process in the infectious disease Leishmaniasis.     

A pharmacokinetic study to correlate the hypoglycemic effect of phlorizin in rats: Identification of metabolites as inhibitors of sodium/glucose cotransporters

Phlorizin (PRZ) is a natural product that belongs to a class of dihydrochalcones. The unique pharmacological property of PRZ is to block glucose absorption or reabsorption through specific and competitive inhibitors of the sodium/glucose cotransporters (SGLTs) in the intestine (SGLT1) and kidney (SGLT2). This results in glycosuria by inhibiting renal reabsorption of glucose and can be used as an adjuvant treatment for type 2 diabetes. The pharmacokinetic profile, metabolites of the PRZ, and efficacy of metabolites towards SGLTs are unknown. Therefore, the present study on the characterization of hitherto unknown in vivo metabolites of PRZ and pharmacokinetic profiling using liquid chromatography-electrospray ionization tandem mass spectrometry (LC/ESI/MS/MS) and accurate mass measurements is undertaken. Plasma, urine, and feces samples were collected after oral administration of PRZ to Sprague–Dawley rats to identify in vivo metabolites. Furthermore, in silico efficacy of the identified metabolites was evaluated by docking study. PRZ at an intraperitoneal dose of 400 mg/kg showed maximum concentration in the blood to 439.32 ± 8.84 ng/mL at 1 h, while phloretin showed 14.38 ± 0.33 ng/mL at 6 h. The pharmacokinetic profile of PRZ showed that the maximum concentration lies between 1 and 2 h after dosing. Decreased blood glucose levels and maximum excretion of glucose in the urine were observed when the PRZ and metabolites were observed in plasma. The identification and characterization of PRZ metabolites by LC/ESI/MS/MS further revealed that the phase I metabolites of PRZ are hydroxy (mono-, di-, and tri-) and reduction. Phase II metabolites are O-methylated, O-acetylated, O-sulfated, and glucuronide metabolites of PRZ. Further docking study revealed that the metabolites diglucuronide metabolite of mono-hydroxylated PRZ and mono-glucuronidation of PRZ could be considered novel inhibitors of SGLT1 and SGLT2, respectively, which show better binding affinities than their parent compound PRZ and the known inhibitors.     

Ligand-Promoted [Pd]-Catalyzed α-Alkylation of Ketones through a Borrowing-Hydrogen Approach

A new class of palladium complexes bearing bidentate 2-hydroxypyridine based ligands have been prepared and fully characterized. The applications of these new complexes towards ketone alkylation reactions with alcohols through a metal-ligand cooperative borrowing-hydrogen (BH) process were demonstrated.     

Gold-Catalyzed Formal [4+2] Cycloaddition as Access to Antitumor-Active Spirocyclic Oxindoles from Alkynes and Isatin-Derived Ketimines

Due to its excellent bioactivity profile, which is increasingly utilized in pharmaceutical and synthetic chemistry, spirooxindole is an important core scaffold. We herein describe an efficient method for the construction of highly functionalized new spirooxindolocarbamates via a gold-catalyzed cycloaddition reaction of terminal alkynes or ynamides with isatin-derived ketimines. This protocol has a good functional group compatibility, uses readily available starting materials, mild reaction conditions, low catalyst loadings and no additives. It enables the transformation of various functionalized alkyne groups into cyclic carbamates. Gram-scale synthesis was achieved and DFT calculations verify the feasibility of the mechanistic proposal. Some of the target products exhibit good to excellent antiproliferative activity on human tumor cell lines. In addition, one of the most active compounds displayed a remarkable selectivity towards tumor cells over normal ones.